Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial.

doi:10.1007/s00277-014-2055-7

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial.

Annals of hematology - 1 Aug 2014

Aslanyan Mariam G, Kroeze Leonie I, Langemeijer Saskia M C, Koorenhof-Scheele Theresia N, Massop Marion, van Hoogen Patricia, Stevens-Linders Ellen, van de Locht Louis T, Tönnissen Evelyn, van der Heijden Adrian, da Silva-Coelho Pedro, Cilloni Daniela, Saglio Giuseppe, Marie Jean-Pierre, Tang Ruoping, Labar Boris, Amadori Sergio, Muus Petra, Willemze Roel, Marijt Erik W A, de Witte Theo, van der Reijden Bert A, Suciu Stefan, Jansen Joop H

Abstract excerpt

We assessed the prognostic impact of TET2 mutations and mRNA expression in a prospective cohort of 357 adult AML patients < 60 years of age enrolled in the European Organization For Research and Treatment of Cancer (EORTC)/Gruppo Italiano Malattie Ematologiche dell' Adulto (GIMEMA) AML-12 06991 clinical trial. In addition the co-occurrence with other genetic defects and the functional consequences of TET2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 5-Methylcytosine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytosine

Share to Dioxygenases

Share to DNA (Cytosine-5-)-Methyltransferases

Share to DNA Methyltransferase 3A

Share to Gene Expression Regulation, Leukemic

Share to Multicenter Studies as Topic

Share to RNA, Neoplasm

Source

Open in PubMed

Identifiers

PMID: 24994606
DOI: 10.1007/s00277-014-2055-7

Genes

TET2
IDH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial.PMID 24994606Read ↗

TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.Semantic proximity Read ↗

Loss of TET2 with reduced genomic 5-hmC is associated with adverse-risk AML.Semantic proximity Read ↗

Acute myeloid leukaemia: recent data on prognostic gene mutations, in relation to stratified therapies for elderly patients.Semantic proximity Read ↗

TET2 mutation in acute myeloid leukemia: biology, clinical significance, and therapeutic insights.Semantic proximity Read ↗

TET2 mutations in cytogenetically normal acute myeloid leukemia: clinical implications and evolutionary patterns.Semantic proximity Read ↗

TET2 mutations contribute to adverse prognosis in acute myeloid leukemia (AML): results from a comprehensive analysis of 502 AML cases and the Beat AML public databaseSemantic proximity Read ↗

Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.Semantic proximity Read ↗

Clinical Implication of DNMT3A and TET2 Genes Mutations in Cytogenetically Normal Acute Myeloid Leukemia.Semantic proximity Read ↗

Prognostic significance of Tet methylcytosine dioxygenase 2 (TET2) gene mutations in adult patients with acute myeloid leukemia: a meta-analysis.Semantic proximity Read ↗

The prognostic impact of tet oncogene family member 2 mutations in patients with acute myeloid leukemia: a systematic-review and meta-analysisSemantic proximity Read ↗

TET2 expression is a potential prognostic and predictive biomarker in cytogenetically normal acute myeloid leukemiaSemantic proximity Read ↗

A meta-analysis of TET2 mutations shows a distinct distribution pattern in de novo acute myeloid leukemia and chronic myelomonocytic leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.